Latest for PACT Pharma

Endpoints News: Neoantigen player PACT Pharma woos Tim Moore from Kite to run technical ops
Highlight

Endpoints News: Neoantigen player PACT Pharma woos Tim Moore from Kite to run technical ops

Tim Moore, who oversaw the CAR-T buildout at Kite, will officially become PACT's president and chief technical officer.
MedCityNews: Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study
Highlight

MedCityNews: Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study

PACT has started dosing patients in an early-stage clinical trial of a product candidate designed to be targeted to proteins in cancer cells unique...
FierceBiotech: A personalized CAR-T to attack every solid tumor? PACT Pharma has a plan
Highlight

FierceBiotech: A personalized CAR-T to attack every solid tumor? PACT Pharma has a plan

PACT Pharma is developing a method for taking T cells from patients with solid tumors and engineering them to be able to recognize and attack those...
Nina Kjellson: "Jumping together" to move the field of personalized cancer therapy
Highlight

Nina Kjellson: "Jumping together" to move the field of personalized cancer therapy

We at Canaan are “all in” on the notion that diversity of knowledge and experience breeds the best results. With this as our core value, PACT...
Activity

Endpoints News: Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology R&D

Activity

BioCentury: Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

Activity

BioCentury: Why GV and Canaan backed PACT Pharma's hyperpersonalized cancer approach